Anixa Biosciences, Inc.

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com

U. Of Texas Research Branch Maintains Hectic Partnering Pace The increasingly busy University of Texas MD Anderson Cancer Center inked three new alliances with biopharmaceutical companies in the pas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Novartis Pays $30m To Partne